Dec 20- Walgreen Co, the largest U.S. drugstore operator, reported higher quarterly sales on Friday, but an increase in promotions and a slowdown in the introduction of higher-profit generic drugs cut into its gross profit margin. Wasson said the business environment was challenging and said Walgreen would focus on containing costs to protect margins.» Read More
Big pharma analysts keep close tabs on prescription trends. Many of them issue weekly reports to clients about what's up, what's down, what's holding steady. Investors use the data as a leading indicator for what quarterly sales and profits might look like. So, check out what A.G. Edwards' Joe Tooley is writing in his most recent "Weekly Prescription Trends" report.Tooley titles it, "Lipitor Continues to Decline, Can Simvastatin (the generic version of Zocor) Surpass It?"
So, for the first time we are getting a clue about how much GlaxoSmithKline will charge for the over-the-counter diet pill Alli, at least at drugstore.com.According to the pricing on the site, where you can actually pre-order your Alli (it won't be available until next month), it'll cost about 83 cents per pill (60 capsules for $49.99). You're supposed to take about three a day, one at every mealtime. But if you buy in bulk (120 pills), the price goes down to about 62 cents apiece. Drugstore.com is also offering free shipping.
Earnings updates and contract wins were some of the catalysts behind the most actively traded stocks on Thursday.
Good morning everyone. Today--Thursday--is a big day for our contestants. The trades they execute prior to 4pm will be the last trades that will impact their total portfolio value based on their performance on Friday. And, the race at the top gets tighter each day. Only $22K separates the top three positions. Nancy Beaumont holds first place for the 3rd straight day on the 9.75% gain of The Men's Wearhouse. Nancy looks like she may maintain her first position with Gymboree up almost 10% in extended hours.
Several of our CNBC Million Dollar Portfolio Challenge finalists are "betting" on gaming stocks for a big finish--so they can win a cool $1,000,000. Gamestop is the stock of choice with earnings coming out. Also, The Men's Wearhouse is "wearing" well with the top two contestants. Here's a look at the top standings and current portfolio values. The contest ends this Friday, so the clock is ticking!! (video below with Margaret Brennan wrapping it all up for you)
The CEO of GlaxoSmithKline and a prominent British medical journal are criticizing a recent study that said Glaxo's widely prescribed diabetes drug Avandia is linked to a greater risk of heart attack and possibly death.
In the middle of the Avandia blowup, GlaxoSmithKline this week is launching the new over-the-counter diet pill "Alli." The company says it's spending 150 million bucks on the first-year marketing of the formerly prescription-only Xenical from Roche.A big chunk of that is going toward a multi-pronged educational campaign to convince dieters they have to change their eating habits and exercise if they want to get the maximum benefit from Alli. That's crucial with this drug because the more fat you eat, the worse the gastrointestinal side effects. Clue: Glaxo is telling Alli users to wear dark pants and bring an extra pair to work. The company has gone so far as to set up an exhibit in New York City this week where people can get more information about Alli.
Good morning all. Here's what's happening on our finals leaderboard with three days of trading left. Nancy Beaumont--pictured left--remains in first place--even with losing almost $30K on Pacific Sunwear Tuesday. And Serge Amelyan moves back into 2nd on an almost $5K gain on Vanda Pharma, and helped by Steven Lee's $76K loss on Neurochem.
Women looking for a simple way to avoid their menstrual period could soon have access to the first birth control pill designed to let women suppress monthly bleeding indefinitely.
The company built by the world's richest man takes on the world's largest democracy, and it's a case of cyber culture clash. India-based itVAR News (an IT website) says Microsoft is billing computer retailers in the town of Gujarat thousands of dollars, accusing them of installing pirated Windows software.The retailers have responded with a strike, a boycott and general outrage, though no one appears to be denying the accusations. One Indian retailer put it this way, "Since we are not charging anything extra for installing the software, it means that we are actually not trading in pirated software. For us, this is just a 'sewa' (selfless act) that we are offering to our customers. Besides, the pricing of their operating systems is way too high for Indian markets."
So, let's start with GlaxoSmithKline's Avandia. The stock is rebounding a little bit today after the pummeling it took yesterday. Once again, the New England Journal of Medicine study saw an "embargo break" by another media outlet. That means the news hit in the middle of the trading day yesterday, catching just about everyone by surprise. The embargo was supposed to have lifted at 5 p.m. ET yesterday, which would have given all of the stakeholders -- chiefly Glaxo -- the ability to issue their prepared press releases at the same time.
So, who's leading the pack as the CNBC Million Dollar Portfolio Challenge heads into its final days (only four left)? Well, we have the up to date standings along with a video clip with the ins and outs. We also have the leaders of the Second Chance Showdown. This is for the contestants who didn't make it into the finals--but can win a Sony Home Theatre Entertainment system. The winner in each category will have to come up with the portfolio with the largest value.
Asset sales and earnings reports catalyzed the most actively traded stocks on Tuesday.
Good morning. Chinese gaming stocks are in the spotlight Monday as The9 propelled Nancy Beaumont to the top of the pack on its 10.31% gain. The9 was up on the news that Electronic Arts agreed to buy a $167M stake in the company, and also licensed a soccer game to The9. Steven Lee managed to hold onto second even though he was all in cash after Friday's trading. He has now gone all-in on Neurochem.
GlaxoSmithKline's widely prescribed diabetes drug Avandia is linked to a greater risk of heart attack and possibly death, a new scientific analysis revealed, and the U.S. government issued a safety alert.
Shares of drug developers Wyeth and Elan jumped Monday after the companies said they plan on asking for approval to move their Alzheimer's treatment candidate bapineuzumab into late-stage studies.
M&A news and drug trial updates provided some of the catalysts behind the most actively traded stocks on Monday.
It sits there in front of you: a plate filled to the overflow point with chili -- and under it, two cheeseburger patties, fried potatoes and one egg, over easy.What are you about to do?
Here's our contest stock report for both the finals and Second Chance Showdown. Acxiom proved to be a winner for several finalsts--and you can see why. It was up 18%. But those who had ADS did even better as that stock was up 24% on news of a merger. Weak earnings took a toll on the worst performing stocks--while the most active and widely held reamined the same.
Cramer answers viewers' questions about Nutrisystem and Syneron. Plus, praise for the men and women in uniform serving in Iraq.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.